Title: Veterinary Quarterly

Title: Virchows Archiv

ISO Abbreviated Title:

JCR Abbreviated Title:

ISSN:

Journal Country

Language:

Publisher:

Publisher Address:

Subject Categories:

: Impact Factor

? Fritzsche, F.R., Dietel, M. and Kristiansen, G. (2008), Where we publish - An analysis of the publications of German institutes of pathology. Virchows Archiv, 452 (4), 363-368.

Full Text: 2008\Vir Arc452, 363.pdf

Abstract: Pathologists provide the link between the clinical and the natural science aspect of medicine and are often integrated in translational research projects. We wanted to analyse the spread and position of research led by pathologists in the scientific literature. Publications from institutes of pathology of 21 randomly chosen German university cities between 2004 and 2006 were analysed. To validate our findings we subsequently extended our analysis to 45 university cities from Italy, France and the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). We detected publications directed by pathologists in numerous biomedical journals, most of which not categorised as “pathology” journals. In the analyses from Germany and Italy, Virchows Archiv led the ranking in terms of absolute number of publications. Meanwhile, Anticancer Research and the International Journal of Cancer took the lead concerning publications from pathologists from the Nordic countries. Our results mirror the wide diversification in scientific pathology and the overlap with other medical subspecialties, especially oncology, cell biology and biochemistry. This explains the problem of defining “pathology” journals and deducting pathological research activity from these publications. However, the general notion that pathology journals are the most important communication medium of pathology research was affirmed.

Keywords: Analysis, Bibliometric, Bibliometric Analysis, Biology, Biomedical, Biomedical Journals, Countries, European-Union, Finland, France, Germany, Impact Factors, Italy, Journals, Journals, Literature, Medical, Medicine, Number of Publications, Oncology, Pathology, Productivity, Publications, Ranking, Research, Research Activity, Research Projects, Science, Scientific Literature, Sweden, Translational Research, University

Title: Virology Journal

ISO Abbreviated Title:

JCR Abbreviated Title:

ISSN:

Journal Country/Territory:

Language:

Publisher:

Publisher Address:

Subject Categories:

: Impact Factor

? Chen, E.Q., Wang, L.C., Lei, J., Xu, L. and Tang, H. (2009), Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virology Journal, 6, Article Number: 163.

Full Text: 2009\Vir J6, 163.pdf

Abstract: Background: Currently, there are no conclusive results on the efficacy of adefovir dipivoxil (ADV) plus lamivudine (LAM) in LAM-resistant patients with chronic hepatitis B (CHB). The aim of study was to evaluate the efficacy of rescue therapy with ADV plus LAM compared to ADV monotherapy in LAM-resistant CHB patients. Results: We searched PUBMED, EMBASE, Web of Science, CNKI (National Knowledge Infrastructure), VIP database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Six eligible trials (442 patients in total) were included and evaluated for methodologic quality and heterogeneity. Greater virological response and lower emergence rate of ADV-associated mutants was observed in ADV plus LAM compared to ADV monotherapy (both P < 0.05). On the contrary, the rate of ALT normalization, HBeAg clearance and seroconversion were all similar between ADV plus LAM and ADV (all P > 0.05). Additionally, adding-on or switch-to ADV was both well tolerated. Conclusion: the combination of ADV with LAM was superior in inhibiting HBV replication and preventing drug resistance as compared to ADV alone for LAM-resistant CHB patients.

Keywords: Cochrane, Database, Drug, Drug Resistance, Efficacy, Embase, Failure, HBV, Knowledge, Meta Analysis, Meta-Analysis, Monotherapy, Mutants, Patients, Recommendations, Resistance, Science, Systematic, Therapy, Web of Science

? Zhao, S.S., Tang, L.H., Fan, X.G., Chen, L.Z., Zhou, R.R. and Dai, X.H. (2010), Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: A systematic review. Virology Journal, 7, Article Number: 211.

Full Text: 2010\Vir J7, 211.pdf

Abstract: Background: Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B. Results: To evaluate the comparison of the efficacy of LAM and LdT in the treatment of chronic hepatitis B by a systematic review and meta-analysis of clinical trials, we searched PUBMED (from 1990 to April 2010), Web of Science (from 1990 to April 2010), EMBASE (from 1990 to April 2010), CNKI (National Knowledge Infrastructure) (from 1990 to April 2010), VIP database (from 1990 to April 2010), WANFANG database (from 1990 to April 2010), The Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. At the end of one-year treatment, LdT was better than LAM at the biochemical response, virological response, HBeAg loss, therapeutic response, while less than at the viral breakthrough and viral resistance, but there was no significant difference in the HBeAg seroconversion and HBsAg response. LdT was better than LAM at the HBeAg seroconversion with prolonged treatment to two years. Conclusions: In summary, LdT was superior in inhibiting HBV replication and preventing drug resistance as compared to LAM for CHB patients. But LdT may cause more nonspecific adverse events and can lead to more CK elevation than LAM. It is thus recommended that the LdT could be used as an option for patients but adverse events, for example CK elevation, must be monitored.

Keywords: Adverse Events, Bias, Chinese Patients, Clinical Trials, Clinical-Trials, Cochrane, Database, Drug, Drug Resistance, Drugs, Efficacy, Embase, HBV, Knowledge, Lead, Meta Analysis, Meta-Analysis, Patients, Prevention, Public Health, Quality, Resistance, Review, Science, Systematic, Systematic Review, Treatment, Virus, Web of Science

? Zhao, S.S., Tang, L.H., Dai, X.H., Wang, W., Zhou, R.R., Chen, L.Z. and Fan, X.G. (2011), Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A systematic review. Virology Journal, 8, Article Number: 111.

Full Text: 2011\Vir J8, 111.pdf

Abstract: Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However, there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total, of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67), P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14], HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91), P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide evolving standards of care for chronic hepatitis B.

Keywords: Analysis, Clinical Trials, Clinical-Trials, Cochrane, Database, Dipivoxil, Disoproxil-Fumarate, Drugs, Efficacy, Embase, HIV, Interferon, Lamivudine, Meta Analysis, Meta-Analysis, Metaanalysis, Patients, Public Health, Quality, Review, Science, Standards, Systematic, Systematic Review, Telbivudine, Treatment, Virus Infection, Web of Science

? Liu, F., Wang, X.W., Wei, F., Hu, H.D., Zhang, D.Z., Hu, P. and Ren, H. (2014), Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: A meta-analysis. Virology Journal, 11, Article Number: 59.

Full Text: 2014\Vir J11, 59.pdf

Abstract: Background: Currently, there is no consensus on the efficacy and resistance of de novo combination therapy versus monotherapy for treatment naive patients of chronic hepatitis B (CHB). Objectives: The aim of this study was to evaluate the effectiveness and resistance of de novo combination of lamivudine (LAM) and adefovir dipivoxil (ADV) compared with entecavir (ETV) monotherapy for nucleos(t)ide-naive patients with CHB. Study design: Publications on the effectiveness and resistance of LAM plus ADV versus ETV monotherapy for nucleos(t) ide-naive patients with CHB were identified by a search of PubMed, Embase, the Cochrane Library, Web of science, OVID, and CBM (Chinese Biological Medical Literature) until May 1, 2013. Biochemical response, hepatitis B e antigen seroconversion, and viroligic response were extracted and combined to obtain an integrated result. Viral resistance and safety were reviewed. Results: Five eligible studies (328 patients in total) were included in the analysis. LAM plus ADV combination therapy produced more rapid HBV DNA reduction rate at 12 weeks than that of ETV monotherapy. At 48 weeks, the combination group had superior viroligic response rates compared with ETV group (90.0% vs. 78.9%, P=0.01). The difference in the ALT normalization and HBeAg seroconversion rates was not found. At week 96, LAM + ADV was more effective than ETV in ALT normalization [RR = 1. 11, 95% CI (1.02, 1.21), P = 0.01] and HBeAg seroconversion [RR = 2.00, 95% CI (1.26, 3.18, P=0.003)], and no significant difference was found in the virologic response (P = 0.23). No viral resistance occurred in combination therapy and six patients in ETV group were experienced with viral breakthrough. Both groups were well tolerated. Conclusion: The de novo LAM plus ADV combination therapy for treatment-naive patients with CHB was greater than ETV monotherapy in both biochemical response and HBeAg seroconversion rate up to 96 weeks. The rate of emergence of viral resistance in the combination group was less than that in the ETV monotherapy.

Keywords: Adefovir Dipivoxil, Analogs, Analysis, Breakthrough, Chinese, Chronic, Chronic Hepatitis, Chronic Hepatitis B, Combination, Combination Therapy, Consensus, De Novo, Design, DNA, E-Antigen, Effectiveness, Efficacy, Entecavir, Groups, HBV, Hepatitis, Hepatitis B, Lamivudine, Literature, Management, Mar, Medical, Meta Analysis, Meta-Analysis, Metaanalysis, Naive, Normalization, P, Patients, Plus Adefovir, Positive Chronic Hepatitis, Prophylaxis, Publications, Pubmed, Rates, Reduction, Resistance, Response, Results, Safety, Science, Therapy, Treatment, Treatment Failure, Viral, Virological Response, Virus-DNA, Web Of Science